Pancreatitis - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pancreatitis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Pancreatitis - Pipeline Review, H1 2016', provides an overview of the Pancreatitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Pancreatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pancreatitis
- The report reviews pipeline therapeutics for Pancreatitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Pancreatitis therapeutics and enlists all their major and minor projects
- The report assesses Pancreatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Pancreatitis

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Pancreatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pancreatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Pancreatitis Overview 7
Therapeutics Development 8
Pipeline Products for Pancreatitis - Overview 8
Pipeline Products for Pancreatitis - Comparative Analysis 9
Pancreatitis - Therapeutics under Development by Companies 10
Pancreatitis - Therapeutics under Investigation by Universities/Institutes 11
Pancreatitis - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Pancreatitis - Products under Development by Companies 15
Pancreatitis - Products under Investigation by Universities/Institutes 16
Pancreatitis - Companies Involved in Therapeutics Development 17
Angion Biomedica Corp. 17
Atox Bio Inc. 18
Bharat Serums And Vaccines Limited 19
CalciMedica, Inc. 20
Dynavax Technologies Corporation 21
Generon (Shanghai) Corporation Ltd. 22
GlaxoSmithKline Plc 23
Pharming Group N.V. 24
Pancreatitis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
AB-103 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AEM-2802 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AEM-2814 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ANG-3070 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
C1 esterase inhibitor (recombinant) - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CM-128 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Drugs to Inhibit Kynurenine 3-Monooxygenase for Acute Pancreatitis - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DV-1179 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
F-652 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GSK-2795039 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
GSK-6288B - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ND-07 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
P-2pal18S - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
PZ-235 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
SBP-101 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
SBP-102 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
SP-20201 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ulinastatin - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Pancreatitis - Recent Pipeline Updates 60
Pancreatitis - Dormant Projects 68
Pancreatitis - Discontinued Products 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables

Number of Products under Development for Pancreatitis, H1 2016 8
Number of Products under Development for Pancreatitis - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Comparative Analysis by Unknown Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Pancreatitis - Pipeline by Angion Biomedica Corp., H1 2016 17
Pancreatitis - Pipeline by Atox Bio Inc., H1 2016 18
Pancreatitis - Pipeline by Bharat Serums And Vaccines Limited, H1 2016 19
Pancreatitis - Pipeline by CalciMedica, Inc., H1 2016 20
Pancreatitis - Pipeline by Dynavax Technologies Corporation, H1 2016 21
Pancreatitis - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2016 22
Pancreatitis - Pipeline by GlaxoSmithKline Plc, H1 2016 23
Pancreatitis - Pipeline by Pharming Group N.V., H1 2016 24
Assessment by Monotherapy Products, H1 2016 25
Number of Products by Stage and Target, H1 2016 27
Number of Products by Stage and Mechanism of Action, H1 2016 29
Number of Products by Stage and Route of Administration, H1 2016 31
Number of Products by Stage and Molecule Type, H1 2016 33
Pancreatitis Therapeutics - Recent Pipeline Updates, H1 2016 60
Pancreatitis - Dormant Projects, H1 2016 68
Pancreatitis - Discontinued Products, H1 2016 69